Filing Flows › Lipocine (LPCN) › Q1 2026
Lipocine (LPCN) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Lipocine (LPCN) reported revenue of $119K for the first quarter 2026 (Q1 2026), +27% from a year earlier and -90% from the quarter before.
Lipocine, Q1 2026: revenue $119K (+27% year over year), net loss $3.7M, operating cash flow −$2.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $119K | -90% | +27% |
| Operating profit | −$3.8M | — | — |
| Net earnings | −$3.7M | — | — |
| Operating cash flow | −$2.3M | — | — |
What changed
Revenue was $119K in Q1 2026, up 27% year over year and down 90% from the previous quarter.
Operating costs exceeded revenue by $3.8M, an operating margin of -3224.1%. Total costs grew 82% against revenue growth of 27%. The fastest-growing cost line was Research & development (+160%). The quarter ended with a net loss of $3.7M, wider than the previous quarter's $2.4M loss.
Operating cash flow was −$2.3M. Non-cash charges added back $15K of depreciation and amortization and $65K of share-based compensation. Working capital and other items added $1.3M.
Questions
What was Lipocine's revenue in the first quarter 2026?
Lipocine (LPCN) reported revenue of $119K for the first quarter 2026 (Q1 2026), +27% from a year earlier and -90% from the quarter before.
Source: Lipocine 10-Q on SEC EDGAR.